多西他赛治疗胃癌的研究进展。
Review of docetaxel in the treatment of gastric cancer.
机构信息
Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA;
出版信息
Ther Clin Risk Manag. 2008 Oct;4(5):999-1007. doi: 10.2147/tcrm.s3226.
Abstract
Gastric cancer is a global health problem accounting for 800,000 cancer related deaths annually. Often diagnosed at an advanced stage, the treatment of gastric cancer with chemotherapy is directed towards palliating cancer related symptoms with only modest improvements in survival. In addition, no regimen has emerged as a globally accepted standard. New therapeutic options are desperately needed for the treatment of gastric cancer. Docetaxel given in combination has recently emerged as a new option for patients with advanced gastric cancer. This review focuses on the treatment of advanced gastric cancer utilizing docetaxel-based therapy and the novel additions of biotherapy to the existing cytotoxic platforms. In addition, the current investigations of docetaxel for the treatment of potentially curable gastric cancer will be discussed.
摘要
胃癌是一个全球性的健康问题，每年导致 80 万人因癌症死亡。胃癌通常在晚期诊断，化疗治疗胃癌的目的是缓解癌症相关症状，只有适度提高生存。此外，没有一种方案被全球公认为标准。迫切需要新的治疗选择来治疗胃癌。多西紫杉醇联合治疗最近成为晚期胃癌患者的一种新选择。本综述重点介绍了基于多西紫杉醇的治疗晚期胃癌的方法，以及将生物疗法添加到现有的细胞毒性平台的新方法。此外，还将讨论目前对多西紫杉醇治疗潜在可治愈胃癌的研究。
相似文献
1
Review of docetaxel in the treatment of gastric cancer.
Ther Clin Risk Manag. 2008 Oct;4(5):999-1007. doi: 10.2147/tcrm.s3226.
2
Chemotherapy for advanced gastric cancer.
Cochrane Database Syst Rev. 2010 Mar 17(3):CD004064. doi: 10.1002/14651858.CD004064.pub3.
3
RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer.
Oncotarget. 2018 Mar 8;9(20):15208-15218. doi: 10.18632/oncotarget.24622. eCollection 2018 Mar 16.
4
Gastric cancer. Treatment of advanced disease and new drugs.
Front Biosci. 2005 Sep 1;10:3122-6. doi: 10.2741/1768.
5
Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
Lung Cancer. 2005 Dec;50S2:S3-S8.
6
Advances in the treatment of gastric cancer.
Curr Opin Gastroenterol. 2018 Nov;34(6):465-468. doi: 10.1097/MOG.0000000000000475.
7
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Asian Pac J Cancer Prev. 2014;15(20):8661-6. doi: 10.7314/apjcp.2014.15.20.8661.
8
The treatment of advanced gastric cancer: new findings on the activity of the taxanes.
Oncologist. 2004;9 Suppl 2:9-15. doi: 10.1634/theoncologist.9-suppl_2-9.
9
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
Eur J Cancer. 2008 Jan;44(2):182-94. doi: 10.1016/j.ejca.2007.11.001.
10
First-line chemotherapy for advanced-stage non-small-cell lung cancer: focus on docetaxel.
Clin Lung Cancer. 2005 Dec;7 Suppl 3:S77-82. doi: 10.3816/clc.2005.s.014.
引用本文的文献
1
The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape.
Front Immunol. 2024 Mar 26;15:1358511. doi: 10.3389/fimmu.2024.1358511. eCollection 2024.
2
An effective strategy for development of docetaxel encapsulated gold nanoformulations for treatment of prostate cancer.
Sci Rep. 2021 Feb 2;11(1):2808. doi: 10.1038/s41598-020-80529-1.
3
Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in gastric and gastroesophageal junction adenocarcinoma.
Mol Clin Oncol. 2020 Sep;13(3):14. doi: 10.3892/mco.2020.2084. Epub 2020 Jul 6.
4
In Search of Panacea-Review of Recent Studies Concerning Nature-Derived Anticancer Agents.
Nutrients. 2019 Jun 25;11(6):1426. doi: 10.3390/nu11061426.
5
Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation.
Biomed Eng Online. 2019 Jan 31;18(1):11. doi: 10.1186/s12938-019-0624-7.
6
Regulates Tumorigenesis and Chemoresistance During Peritoneal Metastasis of Gastric Cancer.
Front Physiol. 2018 Aug 21;9:1132. doi: 10.3389/fphys.2018.01132. eCollection 2018.
7
Upregulation of bone morphogenetic protein 1 is associated with poor prognosis of late-stage gastric Cancer patients.
BMC Cancer. 2018 May 2;18(1):508. doi: 10.1186/s12885-018-4383-9.
8
Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis.
Oncotarget. 2017 Jun 13;8(24):39673-39682. doi: 10.18632/oncotarget.17784.
9
STAT3 is Overactivated in Gastric Cancer Stem-Like Cells.
Cell J. 2016 Winter;17(4):617-28. doi: 10.22074/cellj.2016.3834. Epub 2016 Jan 17.
10
Docetaxel: its role in current and future treatments for advanced gastric cancer.
Gastric Cancer. 2009;12(3):132-41. doi: 10.1007/s10120-009-0521-z. Epub 2009 Nov 5.
本文引用的文献
1
Emerging drugs in the treatment of advanced gastric cancer.
Expert Opin Emerg Drugs. 2008 Mar;13(1):135-44. doi: 10.1517/14728214.13.1.135.
2
Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group.
Br J Cancer. 2008 Feb 12;98(3):542-6. doi: 10.1038/sj.bjc.6604188. Epub 2008 Jan 22.
3
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
N Engl J Med. 2008 Jan 3;358(1):36-46. doi: 10.1056/NEJMoa073149.
4
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
N Engl J Med. 2007 Nov 1;357(18):1810-20. doi: 10.1056/NEJMoa072252.
5
Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.
Ann Oncol. 2008 Jan;19(1):104-8. doi: 10.1093/annonc/mdm449. Epub 2007 Sep 25.
6
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Oncology. 2006;71(5-6):341-6. doi: 10.1159/000108575. Epub 2007 Sep 14.
7
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Am J Clin Oncol. 2007 Aug;30(4):346-9. doi: 10.1097/COC.0b013e318042d582.
8
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
J Clin Oncol. 2007 Aug 1;25(22):3217-23. doi: 10.1200/JCO.2006.08.0135.
9
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
J Clin Oncol. 2007 Aug 1;25(22):3210-6. doi: 10.1200/JCO.2006.08.3956.
10
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
J Clin Oncol. 2007 Aug 1;25(22):3205-9. doi: 10.1200/JCO.2006.10.4968.
Zotero 插件